Sugi Predict

Sugi Predict / Targets / CYSLTR1

CYSLTR1

Cysteinyl leukotriene receptor 1 · Q9Y271 · CYSLTR1 on Sugi Atlas →

63,090 patent compounds predicted against CYSLTR1, 36,166 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL209124 SCHEMBL209124 0.75 20/20
SCHEMBL227362 SCHEMBL227362 0.75 20/20
Pobilukast Pobilukast (SCHEMBL125952) 1.00 17/20
L-648051 L-648051 (SCHEMBL157166) 1.00 17/20
SCHEMBL481322 SCHEMBL481322 0.79 17/20
Pranlukast Pranlukast (SCHEMBL100963) 0.76 17/20
SCHEMBL480843 SCHEMBL480843 0.60 17/20
Acetic Acid Acetic Acid (SCHEMBL524721) 0.58 17/20
SCHEMBL481082 SCHEMBL481082 0.56 17/20
SCHEMBL481374 SCHEMBL481374 0.56 17/20
SCHEMBL481115 SCHEMBL481115 0.55 17/20
SCHEMBL524722 SCHEMBL524722 0.52 17/20
Tipelukast Tipelukast (SCHEMBL154898) 0.78 16/20
Pranlukast Pranlukast (SCHEMBL3693) 0.76 16/20
SCHEMBL3694 SCHEMBL3694 0.74 16/20
SCHEMBL481470 SCHEMBL481470 0.64 16/20
SCHEMBL481105 SCHEMBL481105 0.63 16/20
SCHEMBL481240 SCHEMBL481240 0.62 16/20
SCHEMBL481287 SCHEMBL481287 0.59 16/20
SCHEMBL481338 SCHEMBL481338 0.59 16/20

Clinical trials — most relevant to CYSLTR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Open-label Study of the Effects of Montelukast in Patients With Chronic Cough PHASE4COMPLETED
Investigation to Identify Predictors of Response to a Treatment With Montelukast PHASE4COMPLETED
Effect of Montelukast on the Airway Remodeling PHASE4COMPLETED
TEAM (Trial on Efficacy and Quality of Life Among Asthmatic Patient With Montelukast) PHASE4COMPLETED
Effect of Addition Oral Montelukast to Standard Treatment in Acute Asthma in Hospitalized Preschool Children PHASE4COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
Montelukast for Early Life Wheezing PHASE2/PHASE3COMPLETED
Wheeze and Intermittent Treatment PHASE3COMPLETED
Aspirin for Uncontrolled Asthma PHASE3COMPLETED
Montelukast in Parkinson Disease PHASE2/PHASE3RECRUITING
Effect of Montelukast Versus Co Enzyme in Sepsis PHASE2/PHASE3COMPLETED
Predicting the Response to Montelukast by Genetic Variation in Asthmatics PHASE3COMPLETED
Treatment of Bronchial Asthma With Borage and Echium Seed Oils PHASE1/PHASE2COMPLETED
Treating Exacerbations of Asthma With Oral Montelukast in Children PHASE2COMPLETED
GSK2190915 Neutrophilic Asthma Study PHASE2COMPLETED
Montelukast in Very Low Birthweight Infants PHASE1COMPLETED
MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial) EARLY_PHASE1RECRUITING
Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers EARLY_PHASE1UNKNOWN
Lipid Mediators & Cancer: Montelukast, SPM, and Almonds EARLY_PHASE1NOT_YET_RECRUITING
CysLT1-r Expression Following Allergen Exposure in Asthma and Allergic Rhinitis nanUNKNOWN
Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma nanCOMPLETED
Leukotrienes Pathway in Chinese Children With Sleep-disordered Breathing nanUNKNOWN
Transporter Mediated Uptake of Montelukast nanCOMPLETED
Montelukast in the Treatment of Duodenal Eosinophilia nanCOMPLETED
A Mechanistic Study to Evaluate the Efficacy of Montelukast on Airway Function in Asthma nanUNKNOWN
Gender Differences and SNPs in Asthmatic Patients nanUNKNOWN
Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT nanCOMPLETED
The Severe Asthma Research Program III-Boston Clinical Site nanCOMPLETED
Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial nanCOMPLETED
Effect of Montelukast on Experimentally-Induced RV16 Infection in Asthma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CYSLTR1 binder may also engage these)

ProteinNameSimilarity
Q924T8 — 1.000 Q924T8 →
Q2NNR5 — 1.000 Q2NNR5 →
Q99JA4 — 1.000 Q99JA4 →
Q95N02 — 1.000 Q95N02 →
D4A7K7 — 0.996 D4A7K7 →
Q3U507 — 0.995 Q3U507 →
Q3U6B2 — 0.994 Q3U6B2 →
GPR183 G-protein coupled receptor 183 0.994 landscape →
Q4G072 — 0.993 Q4G072 →
Q61038 — 0.990 Q61038 →
A5PLE7 — 0.990 A5PLE7 →
Q9ESG6 — 0.989 Q9ESG6 →
Q9GK76 — 0.989 Q9GK76 →
LPAR4 Lysophosphatidic acid receptor 4 0.988 landscape →
Q9TTY5 — 0.987 Q9TTY5 →
Q8BFU7 — 0.987 Q8BFU7 →
LPAR6 Lysophosphatidic acid receptor 6 0.987 landscape →
Q8BLG2 — 0.987 Q8BLG2 →
Q8BG55 — 0.987 Q8BG55 →
Q924T9 — 0.986 Q924T9 →
CYSLTR2 Cysteinyl leukotriene receptor 2 0.986 landscape →
P59902 — 0.986 P59902 →
Q920A1 — 0.985 Q920A1 →
GPR65 G-protein coupled receptor 65 0.985 landscape →
Q9BY21 — 0.985 Q9BY21 →
GPR174 Probable G-protein coupled receptor 174 0.984 landscape →
Q9XSD4 — 0.984 Q9XSD4 →
B0UXR0 — 0.984 B0UXR0 →
D4A4Q2 — 0.984 D4A4Q2 →
P2RY10 Putative P2Y purinoceptor 10 0.984 landscape →